CollPlant Biotechnologies is a regenerative medicine company pioneering the use of recombinant human collagen produced in tobacco plants. By harnessing proprietary plant molecular farming technology, CollPlant develops bioactive, biocompatible collagen-based materials for tissue repair and reconstruction. The company’s innovative platform offers a sustainable source of human collagen that avoids the risks and supply limitations associated with animal-derived products.
The company’s flagship products include Vergenix™ Flowable and Vergenix™STR, advanced collagen matrices designed to support wound healing, soft tissue regeneration and aesthetic procedures. In parallel, CollPlant is advancing a pipeline of cross-linkable bioinks for 3D bioprinting applications in orthopedics, plastic surgery and organ engineering. These bioinks are formulated to promote cell attachment and tissue maturation, positioning CollPlant at the forefront of biofabrication technologies.
Founded in 2007 and headquartered in Ness Ziona, Israel, CollPlant maintains operations in the United States to serve global markets. The company collaborates with leading medical device firms, pharmaceutical partners and research institutions to accelerate commercialization of its collagen-based solutions. Strategic alliances span Europe, Asia and North America, reflecting CollPlant’s commitment to addressing unmet clinical needs worldwide.
Under the leadership of Chief Executive Officer Yehiel Tal and co-founder and Chief Science Officer Morad Jaber, CollPlant combines scientific expertise with industrial-scale manufacturing capabilities. The management team’s experience in biotechnology and regenerative medicine supports the company’s long-term vision of transforming patient care through scalable, high-performance collagen products.
AI Generated. May Contain Errors.